{"id":"placebo-for-allopurinol","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to measure the effect of expectation, belief, and the therapeutic context independent of the drug's active ingredient. In this case, it serves as a control comparator in trials evaluating allopurinol's efficacy for urate-lowering therapy. Any observed benefit reflects placebo response rather than direct molecular action.","oneSentence":"A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:45.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in allopurinol efficacy trials (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT07326839","phase":"NA","title":"Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT","status":"NOT_YET_RECRUITING","sponsor":"XueMei Guo","startDate":"2025-12-10","conditions":"Gout, Obesity","enrollment":120},{"nctId":"NCT05818085","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout","status":"COMPLETED","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2023-08-11","conditions":"Gout","enrollment":300},{"nctId":"NCT05586971","phase":"PHASE3","title":"Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-03-30","conditions":"Gout, Hyperuricemia, Gout Flare","enrollment":2202},{"nctId":"NCT05601271","phase":"NA","title":"Effect of Allopurinol on Markers of Mineral and Bone Metabolism","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-03-01","conditions":"Chronic Kidney Diseases, Osteodystrophy, Uric Acid Concentration, Serum, Quantitative Trait Locus 7","enrollment":50},{"nctId":"NCT04956432","phase":"PHASE3","title":"A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-15","conditions":"Gout","enrollment":779},{"nctId":"NCT05943821","phase":"PHASE3","title":"The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2023-09-01","conditions":"Cardiovascular Diseases, Uric Acid","enrollment":1116},{"nctId":"NCT06622603","phase":"PHASE4","title":"The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-15","conditions":"Gout, Uric Acid","enrollment":59},{"nctId":"NCT04217421","phase":"PHASE3","title":"Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"dr. M.J.N.L. Benders","startDate":"2020-02-14","conditions":"Congenital Heart Disease in Children, Neuroprotection","enrollment":236},{"nctId":"NCT03162653","phase":"PHASE3","title":"Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2018-03-25","conditions":"Encephalopathy, Hypoxic-Ischemic, Infant, Newborn, Diseases","enrollment":760},{"nctId":"NCT03648996","phase":"PHASE2","title":"Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2018-11-01","conditions":"Diabetes Mellitus, Type 2, Hyperuricemia","enrollment":34},{"nctId":"NCT04327024","phase":"PHASE2","title":"Study of Verinurad in Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-19","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":159},{"nctId":"NCT05545670","phase":"PHASE2, PHASE3","title":"Allopurinol to Prevent Cirrhosis Related Morbidities","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-15","conditions":"Cirrhosis","enrollment":100},{"nctId":"NCT05511766","phase":"PHASE2, PHASE3","title":"Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-11-15","conditions":"Cirrhosis, Hepatic Encephalopathy, Ascites","enrollment":150},{"nctId":"NCT03990363","phase":"PHASE2","title":"A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-07-23","conditions":"Chronic Kidney Disease","enrollment":861},{"nctId":"NCT03745729","phase":"PHASE4","title":"Allopurinol in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-03-01","conditions":"Acute Coronary Syndrome","enrollment":162},{"nctId":"NCT04052932","phase":"PHASE3","title":"A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-16","conditions":"Gout","enrollment":594},{"nctId":"NCT05414669","phase":"PHASE4","title":"Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL","status":"COMPLETED","sponsor":"Sanglah General Hospital","startDate":"2020-08-06","conditions":"Kidney Calculi","enrollment":35},{"nctId":"NCT02122718","phase":"PHASE4","title":"XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2014-05","conditions":"Ischaemic Stroke","enrollment":464},{"nctId":"NCT03226899","phase":"PHASE4","title":"A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment","status":"TERMINATED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2017-07-19","conditions":"Gout, Chronic Kidney Disease (CKD)","enrollment":242},{"nctId":"NCT04368819","phase":"PHASE2, PHASE3","title":"Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms","status":"UNKNOWN","sponsor":"Ministry of Health, Brazil","startDate":"2021-03-03","conditions":"Refractory Angina","enrollment":40},{"nctId":"NCT03353298","phase":"PHASE2","title":"Lowering Uric Acid in Live Kidney Donors","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-01-17","conditions":"Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney","enrollment":71},{"nctId":"NCT02038179","phase":"PHASE2, PHASE3","title":"Center of Research Translation (CORT) Project 2","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-07","conditions":"Pre-hypertension, JNC 7 Stage I Hypertension","enrollment":99},{"nctId":"NCT02017171","phase":"PHASE3","title":"A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes","status":"COMPLETED","sponsor":"Alessandro Doria","startDate":"2014-02","conditions":"Diabetic Nephropathies, Coronary Artery Disease","enrollment":530},{"nctId":"NCT01637623","phase":"PHASE2","title":"Study of Cardiovascular Disease and Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2012-06","conditions":"Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension","enrollment":87},{"nctId":"NCT02956278","phase":"PHASE4","title":"The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-11","conditions":"Chronic Gout, Hyperuricemia","enrollment":27},{"nctId":"NCT02533648","phase":"PHASE3","title":"Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-09-16","conditions":"Type 2 Diabetes Mellitus","enrollment":31},{"nctId":"NCT01332799","phase":"PHASE4","title":"Xanthine Oxidase Inhibition in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Roberto S Kalil","startDate":"2011-02","conditions":"Complications of Renal Transplant","enrollment":20},{"nctId":"NCT02237339","phase":"PHASE4","title":"Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-09","conditions":"Hypertension, Hypertrophy, Left Ventricular","enrollment":72},{"nctId":"NCT00643123","phase":"PHASE4","title":"Allopurinol Add-on Treatment for Refractory Mania","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2007-09","conditions":"Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania","enrollment":40},{"nctId":"NCT00819585","phase":"PHASE2","title":"A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12","conditions":"Gout","enrollment":432},{"nctId":"NCT01550107","phase":"PHASE4","title":"Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-02-01","conditions":"Sarcopenia","enrollment":124},{"nctId":"NCT01988402","phase":"PHASE4","title":"Does Allopurinol Prolong a Treated, Acute Gout Flare?","status":"COMPLETED","sponsor":"59th Medical Wing","startDate":"2007-12","conditions":"Gout","enrollment":35},{"nctId":"NCT02063997","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-03","conditions":"Gout","enrollment":248},{"nctId":"NCT00288184","phase":"PHASE2","title":"Uric Acid in Essential Hypertension in Children","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-09","conditions":"Essential Hypertension","enrollment":30},{"nctId":"NCT00288171","phase":"PHASE1, PHASE2","title":"Allopurinol for Renal Transplant Associated Hypertension in Children","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-02","conditions":"Hypertension, Renal Transplant","enrollment":""},{"nctId":"NCT01459796","phase":"PHASE3","title":"Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-11","conditions":"Gout","enrollment":220},{"nctId":"NCT01320722","phase":"PHASE3","title":"Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03","conditions":"Renal Function, Endothelial Function, Blood Pressure","enrollment":242},{"nctId":"NCT00610363","phase":"PHASE2","title":"Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-11","conditions":"Gout","enrollment":83},{"nctId":"NCT01147705","phase":"PHASE4","title":"Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2011-02","conditions":"Peripheral Arterial Disease","enrollment":50},{"nctId":"NCT00829829","phase":"PHASE3","title":"PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-02","conditions":"Intercritical Gout","enrollment":241},{"nctId":"NCT00856206","phase":"PHASE3","title":"Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-03","conditions":"Gout","enrollment":1315},{"nctId":"NCT00958438","phase":"PHASE3","title":"PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-07","conditions":"Gout","enrollment":248},{"nctId":"NCT00855920","phase":"PHASE3","title":"Study Utilizing Rilonacept in Gout Exacerbations","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-03","conditions":"Acute Gout Flare","enrollment":225},{"nctId":"NCT01001338","phase":"PHASE2","title":"Allopurinol Combination Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2009-10","conditions":"Gout","enrollment":227},{"nctId":"NCT01951404","phase":"PHASE4","title":"Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2013-09","conditions":"End Stage Renal Disease, Left Ventricular Hypertrophy","enrollment":80},{"nctId":"NCT00688480","phase":"PHASE4","title":"Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?","status":"COMPLETED","sponsor":"A. D. Struthers","startDate":"2008-01","conditions":"Kidney Disease, Left Ventricular Hypertrophy","enrollment":67},{"nctId":"NCT01987570","phase":"PHASE3","title":"Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2012-04","conditions":"Patients With Grade II Ankle Sprain","enrollment":53},{"nctId":"NCT01510158","phase":"PHASE3","title":"Combining Lesinurad With Allopurinol in Inadequate Responders","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-01","conditions":"Gout","enrollment":607},{"nctId":"NCT00560079","phase":"PHASE4","title":"Efficacy of Allopurinol and Dypiridamole in Acute Mania","status":"COMPLETED","sponsor":"Hospital Espirita de Porto Alegre","startDate":"2003-11","conditions":"Mania","enrollment":180},{"nctId":"NCT00116207","phase":"PHASE3","title":"An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2000-01","conditions":"Diabetic Autonomic Neuropathy","enrollment":44},{"nctId":"NCT02797028","phase":"PHASE4","title":"Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines","status":"UNKNOWN","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2015-01","conditions":"Cardiovascular Disease","enrollment":320},{"nctId":"NCT01399008","phase":"PHASE2","title":"Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-06","conditions":"Gout","enrollment":100},{"nctId":"NCT01457820","phase":"PHASE4","title":"Allopurinol in Acute Coronary Syndrome","status":"TERMINATED","sponsor":"Stephen McSwiggan","startDate":"2012-04","conditions":"Chronic Stable Angina","enrollment":26},{"nctId":"NCT00987415","phase":"PHASE2","title":"Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels","status":"COMPLETED","sponsor":"Duke University","startDate":"2010-05","conditions":"Heart Failure, Elevated Serum Uric Acid","enrollment":253},{"nctId":"NCT01609166","phase":"PHASE2","title":"Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-07","conditions":"Hand-foot Syndrome","enrollment":60},{"nctId":"NCT01451645","phase":"PHASE4","title":"Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-10","conditions":"Intercritical Gout","enrollment":82},{"nctId":"NCT01407874","phase":"PHASE2","title":"A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2011-09","conditions":"Gout, Hyperuricemia, Arthritis","enrollment":20},{"nctId":"NCT01265264","phase":"PHASE2","title":"Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2010-12","conditions":"Gout, Hyperuricemia, Arthritis","enrollment":279},{"nctId":"NCT00241839","phase":"PHASE3","title":"Uric Acid and Hypertension in African Americans","status":"COMPLETED","sponsor":"University of Florida","startDate":"2005-08","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":150},{"nctId":"NCT01077284","phase":"PHASE2","title":"Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-02","conditions":"Hyperuricosuria, Kidney Stones","enrollment":99},{"nctId":"NCT01092221","phase":"PHASE3","title":"Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-05","conditions":"Mania","enrollment":180},{"nctId":"NCT00864825","phase":"PHASE4","title":"Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2009-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":248},{"nctId":"NCT00189007","phase":"PHASE3","title":"Antenatal Allopurinol During Fetal Hypoxia","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2009-10","conditions":"Fetal Hypoxia, Reperfusion Injury","enrollment":222},{"nctId":"NCT00174915","phase":"PHASE3","title":"Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-02","conditions":"Gout","enrollment":1072},{"nctId":"NCT01129648","phase":"PHASE2","title":"Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2010-05","conditions":"Gout","enrollment":87},{"nctId":"NCT01310673","phase":"PHASE4","title":"Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout","status":"COMPLETED","sponsor":"White River Junction Veterans Affairs Medical Center","startDate":"1998-01","conditions":"Gout, Gout Acute","enrollment":57},{"nctId":"NCT00639756","phase":"PHASE2","title":"The Effect of Allopurinol on Insulin Resistance and Blood Pressure","status":"COMPLETED","sponsor":"Hospital Mateo Orfila","startDate":"2008-06","conditions":"Metabolic Syndrome","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":385,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo (for allopurinol)","genericName":"Placebo (for allopurinol)","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes. Used for Control arm in allopurinol efficacy trials (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}